ஆல்வியோ தொழில்நுட்பங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Alveo Technologies Appoints Veteran Biotech and Diagnostics Leader to Board of Directors

Alveo Technologies Appoints Veteran Biotech and Diagnostics Leader to Board of Directors Roche executive Neil Gunn brings quarter-century of commercialization experience to infectious disease testing innovator News provided by Share this article Share this article ALAMEDA, Calif., May 13, 2021 /PRNewswire/ Alveo Technologies, Inc., an infectious disease testing leader, announced today biotechnology, diagnostics and medical device executive Neil Gunn has accepted an appointment to its board of directors. To download a photo of Neil Gunn, click here. Gunn, the retired president of Roche Sequencing Solutions, and current CEO of IDbyDNA, brings more than 25 years of healthcare industry experience to Alveo, with comprehensive knowledge and experience managing global product development, strategy development and commercial operations.

United kingdomNeil gunnRon chiarelloNottingham trent universityPrnewswire alveo technologies incRoche sequencing solutionsDrug administrationPall medical ltdPortsmouth universityGlobal businessRoche molecularRoche sequencingNovartis diagnosticsMarine microbiologyNottingham trentEmergency use authorization

Infectious Disease Testing Leader Alveo Technologies Engages Amendola Communications

Infectious Disease Testing Leader Alveo Technologies Engages Amendola Communications
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Jodi amendolaMarciag rhodesRon chiarelloAmendola communicationsAlveo technologiesஜோடி திருத்தம்ரோன் சியாரெல்லோதிருத்தம் தகவல்தொடர்புகள்ஆல்வியோ தொழில்நுட்பங்கள்

Infectious Disease Testing Leader Alveo Technologies Engages Amendola Communications

La Jolla Institute for Immunology is a winner in XPrize rapid COVID-19 testing contest

The La Jolla Institute for Immunology is a winner in XPrize’s $6 million rapid COVID-19 testing competition. The well-known technology contest organizer named five winning teams in the competition on March 16. The others are ChromaCode and Reliable-LFC, both of Carlsbad, Alveo Technologies of Alameda and Mirimus of Brooklyn, N.Y. Each winner is guaranteed $500,000. They will receive an additional $500,000 over the next few months if they hit milestones for mass-producing their COVID-19 tests. Moreover, a $50 million venture capital fund called the COVID Apollo Project has pledged to work with the XPrize Foundation and others to bring testing innovations to market. The fund includes life sciences investors such as RA Capital and Bain Capital.

Ansari xprizeLos angelesSuzie alarconJolla institute next generation sequencing coreX prize foundationJolla institute for immunologyAlveo technologiesNext generation sequencing coreGoogle lunarXprize rapid covid testingலாஸ் ஏஞ்சல்ஸ்ஸஸீ அலர்கான்ஜொல்லா நிறுவனம் அடுத்தது ஜெநரேஶந் வரிசைப்படுத்துதல் கோர்எக்ஸ் ப்ரைஸ் அடித்தளம்ஜொல்லா நிறுவனம் க்கு நோயெதிர்ப்புஆல்வியோ தொழில்நுட்பங்கள்

Alveo Technologies be well COVID-19 Test Wins XPRIZE Rapid Covid Testing Competition

Share this article Share this article ALAMEDA, Calif., March 17, 2021 /PRNewswire/ Alveo Technologies, Inc. (Alveo) announced today that it has been named a winner of the $6M XPRIZE Rapid COVID Testing Competition for its be.well COVID-19 Test. The be.well™ platform provides individuals access to molecular testing and cloud-based analytics for rapid diagnosis and management of infectious diseases. (PRNewsfoto/Alveo Technologies) The $6 million XPRIZE Rapid Covid Testing Competition challenged any and all innovators across the world to develop frequent, fast, cheap and easy COVID-19 screening solutions to help meet the surging demand for tests and relieve the global supply chain. Twenty finalist teams, including Alveo, were selected out of a pool of 219 semifinalists, with an initial 700 teams signing up. These semifinalists then had two weeks to send their testing kits and protocols to laboratories for clinical validation. Alveo won $500,000 as one of the top five team

United statesUnited kingdomJulianne averillJeff huberRon chiarelloEuropean unionDrug administrationCovid testing competitionEmergency use authorizationChief financial officerCovid testingNext billionNext gen mask challengeAlveo technologiesஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது கிஂக்டம்